February 08, 2012
PARIS, Feb 8
– A drug tipped for widespread use to prevent breast cancer in
post-menopausal women also accelerates loss of bone density, thus
potentially boosting the risk of fractures, a study published today
said.
Exemestane – brand name Aromasin – is part of a drug class called
aromatase inhibitors, which lower levels of the oestrogen that some
breast cancers need in order to grow.
Canadian bone specialists took a look at a group of patients who had
taken part in a study into the effectiveness of exemestane among 4,500
healthy women with a worrying family history of breast cancer. Overall, the big study showed that the drug was highly effective, reducing the risk of breast cancer by almost two-thirds.
The bone sub-study looked at 351 women who had been taking either
exemestane or a dummy lookalike pill and whose bone density was measured
with hi-tech scanners.
After two years, women taking exemestane had a high loss of bone
density at a common fracture point in the wrist called the distal
radius, and also at the lower end of the tibia, compared with their
counterparts on placebo.
The exemestane users also had an eight-per cent decline in the
thickness of cortical bone, which comprises the protective outer shell
of the bones.
That finding in particular is worrying because nearly four out of
every five fractures in old age occur in cortical bone. These accidents
are a huge source of disability.
“Women considering exemestane for the primary prevention of breast
cancer should weigh their individual risks and benefits,” says the
study, headed by Angela Cheung of the University Health Network in
Toronto. “For women taking exemestane, regular bone monitoring plus adequate calcium and vitamin D supplementation are important.”
Source here:
No comments:
Post a Comment